Short answer · Medically reviewed summary · Last updated: 2023-07-13
Schindler disease, also known as Kanzaki disease, is a rare genetic disorder that falls under the category of lysosomal storage diseases. It is caused by mutations in the N-acetylglucosamine-1-phosphotransferase (GNPTAB) gene, which leads to impaired functioning of lysosomes in the body's cells. The prevalence of Schindler disease is extremely low, making it a rare condition.
What is the prevalence of Schindler disease?
Prevalence of Schindler disease: how many people are affected worldwide, differences by sex and region, with sources.
Schindler disease, also known as Kanzaki disease, is a rare genetic disorder that falls under the category of lysosomal storage diseases. It is caused by mutations in the N-acetylglucosamine-1-phosphotransferase (GNPTAB) gene, which leads to impaired functioning of lysosomes in the body's cells.
The prevalence of Schindler disease is extremely low, making it a rare condition. Exact prevalence rates are not well-documented due to its rarity and the lack of comprehensive studies. However, it is estimated to affect fewer than 1 in 1 million individuals worldwide.
Symptoms of Schindler disease can vary widely and may include developmental delays, intellectual disability, seizures, skeletal abnormalities, and liver dysfunction. The severity of the disease can also vary, with some individuals experiencing milder symptoms while others may have more severe manifestations.
Diagnosis of Schindler disease typically involves genetic testing to identify mutations in the GNPTAB gene. Unfortunately, there is currently no cure for Schindler disease, and treatment mainly focuses on managing symptoms and providing supportive care.
Given its rarity, raising awareness about Schindler disease is crucial for early diagnosis and appropriate management. Further research and collaboration among medical professionals are needed to better understand this rare disorder and develop potential therapies.
